Cabaletta Bio (CABA) Cash & Equivalents (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Cash & Equivalents of $133.6 million for Q4 2025, down 18.52% year-over-year from $164.0 million in Q4 2024, and up 121.9% quarter-over-quarter from $60.2 million in Q3 2025.
Cabaletta Bio (CABA) Cash & Equivalents (2018 - 2026) Analysis & Trends
Cabaletta Bio's Cash & Equivalents history runs 8 years deep, the most recent figure standing at $133.6 million for Q4 2025.
- In Q4 2025, Cash & Equivalents fell 18.52% year-over-year to $133.6 million; the TTM figure through Dec 2025 stood at $133.6 million (down 18.52% YoY), while the FY2025 annual figure was $133.6 million, down 18.52% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $133.6 million, up from $60.2 million in the prior quarter.
- The five-year high for Cash & Equivalents was $223.8 million in Q1 2024, with the low at $47.2 million in Q2 2022.
- The 5-year median for Cash & Equivalents is $127.0 million (2021), against an average of $132.1 million.
- The sharpest annual moves came in 2023 and 2025: Cash & Equivalents soared 273.82% in 2023, then slumped 67.1% in 2025.
- Cabaletta Bio's Cash & Equivalents stood at $122.2 million in 2021, then sank by 33.23% to $81.6 million in 2022, then soared by 136.79% to $193.2 million in 2023, then declined by 15.15% to $164.0 million in 2024, then declined by 18.52% to $133.6 million in 2025.
- Business Quant data shows CABA's Cash & Equivalents at $133.6 million in Q4 2025, $60.2 million in Q3 2025, and $194.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | 225.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 225.10 Mn |
| Dec 31, 2025 | 133.60 Mn |
| Sep 30, 2025 | 60.21 Mn |
| Jun 30, 2025 | 194.68 Mn |
| Mar 31, 2025 | 131.83 Mn |
| Dec 31, 2024 | 163.96 Mn |
| Sep 30, 2024 | 183.01 Mn |
| Jun 30, 2024 | 203.23 Mn |
| Mar 31, 2024 | 223.85 Mn |
| Dec 31, 2023 | 193.24 Mn |
| Sep 30, 2023 | 164.39 Mn |
| Jun 30, 2023 | 176.33 Mn |
| Mar 31, 2023 | 93.85 Mn |
| Dec 31, 2022 | 81.61 Mn |
| Sep 30, 2022 | 85.90 Mn |
| Jun 30, 2022 | 47.17 Mn |
| Mar 31, 2022 | 59.55 Mn |
| Dec 31, 2021 | 122.22 Mn |
| Sep 30, 2021 | 118.26 Mn |
| Jun 30, 2021 | 102.81 Mn |